Cargando…
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse e...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675642/ https://www.ncbi.nlm.nih.gov/pubmed/36331798 http://dx.doi.org/10.1007/s40520-022-02272-z |
_version_ | 1784833420088573952 |
---|---|
author | Fuggle, Nicholas Al-Daghri, Nasser Bock, Olivier Branco, Jaime Bruyère, Olivier Casado, Enrique Cavalier, Etienne Cortet, Bernard de Wit, Maarten Giusti, Andrea Halbout, Philippe Harvey, Nicholas C. Hiligsmann, Mickaël Kaufman, Jean-Marc Kurth, Andreas Maggi, Stefania Matijevic, Radmila Minisola, Salvatore Palacios, Santiago Radermecker, Régis Pierre Thomasius, Friederike Tuzun, Sansin Veronese, Nicola Kanis, John A. Reginster, Jean-Yves Rizzoli, René Cooper, Cyrus |
author_facet | Fuggle, Nicholas Al-Daghri, Nasser Bock, Olivier Branco, Jaime Bruyère, Olivier Casado, Enrique Cavalier, Etienne Cortet, Bernard de Wit, Maarten Giusti, Andrea Halbout, Philippe Harvey, Nicholas C. Hiligsmann, Mickaël Kaufman, Jean-Marc Kurth, Andreas Maggi, Stefania Matijevic, Radmila Minisola, Salvatore Palacios, Santiago Radermecker, Régis Pierre Thomasius, Friederike Tuzun, Sansin Veronese, Nicola Kanis, John A. Reginster, Jean-Yves Rizzoli, René Cooper, Cyrus |
author_sort | Fuggle, Nicholas |
collection | PubMed |
description | Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk–benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes. |
format | Online Article Text |
id | pubmed-9675642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-96756422022-11-21 Novel formulations of oral bisphosphonates in the treatment of osteoporosis Fuggle, Nicholas Al-Daghri, Nasser Bock, Olivier Branco, Jaime Bruyère, Olivier Casado, Enrique Cavalier, Etienne Cortet, Bernard de Wit, Maarten Giusti, Andrea Halbout, Philippe Harvey, Nicholas C. Hiligsmann, Mickaël Kaufman, Jean-Marc Kurth, Andreas Maggi, Stefania Matijevic, Radmila Minisola, Salvatore Palacios, Santiago Radermecker, Régis Pierre Thomasius, Friederike Tuzun, Sansin Veronese, Nicola Kanis, John A. Reginster, Jean-Yves Rizzoli, René Cooper, Cyrus Aging Clin Exp Res Review Article Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk–benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes. Springer International Publishing 2022-11-04 2022 /pmc/articles/PMC9675642/ /pubmed/36331798 http://dx.doi.org/10.1007/s40520-022-02272-z Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Fuggle, Nicholas Al-Daghri, Nasser Bock, Olivier Branco, Jaime Bruyère, Olivier Casado, Enrique Cavalier, Etienne Cortet, Bernard de Wit, Maarten Giusti, Andrea Halbout, Philippe Harvey, Nicholas C. Hiligsmann, Mickaël Kaufman, Jean-Marc Kurth, Andreas Maggi, Stefania Matijevic, Radmila Minisola, Salvatore Palacios, Santiago Radermecker, Régis Pierre Thomasius, Friederike Tuzun, Sansin Veronese, Nicola Kanis, John A. Reginster, Jean-Yves Rizzoli, René Cooper, Cyrus Novel formulations of oral bisphosphonates in the treatment of osteoporosis |
title | Novel formulations of oral bisphosphonates in the treatment of osteoporosis |
title_full | Novel formulations of oral bisphosphonates in the treatment of osteoporosis |
title_fullStr | Novel formulations of oral bisphosphonates in the treatment of osteoporosis |
title_full_unstemmed | Novel formulations of oral bisphosphonates in the treatment of osteoporosis |
title_short | Novel formulations of oral bisphosphonates in the treatment of osteoporosis |
title_sort | novel formulations of oral bisphosphonates in the treatment of osteoporosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675642/ https://www.ncbi.nlm.nih.gov/pubmed/36331798 http://dx.doi.org/10.1007/s40520-022-02272-z |
work_keys_str_mv | AT fugglenicholas novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT aldaghrinasser novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT bockolivier novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT brancojaime novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT bruyereolivier novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT casadoenrique novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT cavalieretienne novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT cortetbernard novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT dewitmaarten novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT giustiandrea novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT halboutphilippe novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT harveynicholasc novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT hiligsmannmickael novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT kaufmanjeanmarc novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT kurthandreas novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT maggistefania novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT matijevicradmila novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT minisolasalvatore novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT palaciossantiago novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT radermeckerregispierre novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT thomasiusfriederike novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT tuzunsansin novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT veronesenicola novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT kanisjohna novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT reginsterjeanyves novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT rizzolirene novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis AT coopercyrus novelformulationsoforalbisphosphonatesinthetreatmentofosteoporosis |